alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo.
BACKGROUND
Cell surface sialylation is emerging as an important feature of cancer cell metastasis. Sialyltransferase expression has been reported to be altered in tumours and may account for the formation of sialylated tumour antigens. We have focused on the influence of alpha-2,3-sialyltransferase ST3Gal III in key steps of the pancreatic tumorigenic process.


RESULTS
ST3Gal III overexpressing pancreatic adenocarcinoma cell lines Capan-1 and MDAPanc-28 were generated. They showed an increase of the tumour associated antigen sialyl-Lewis(x). The transfectants' E-selectin binding capacity was proportional to cell surface sialyl-Lewis(x) levels. Cellular migration positively correlated with ST3Gal III and sialyl-Lewis(x) levels. Moreover, intrasplenic injection of the ST3Gal III transfected cells into athymic nude mice showed a decrease in survival and higher metastasis formation when compared to the mock cells.


CONCLUSIONS
In summary, the overexpression of ST3Gal III in these pancreatic adenocarcinoma cell lines underlines the role of this enzyme and its product in key steps of tumour progression such as adhesion, migration and metastasis formation.
Pérez-Garay
Marta
M
Biochemistry and Molecular Biology Unit, Department of Biology, University of Girona, Girona, Spain.
Arteta
Beatriz
B
Pagès
Lluís
L
de Llorens
Rafael
R
de Bolòs
Carme
C
Vidal-Vanaclocha
Fernando
F
Peracaula
Rosa
R
D000818:Animals; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D002465:Cell Movement; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D010190:Pancreatic Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology*; D051381:Rats; D012799:Sialyltransferases / Q000235:genetics / Q000378:metabolism*; D013534:Survival; D000094663:beta-Galactoside alpha-2,3-Sialyltransferase
D012799:Sialyltransferases; D000094663:beta-Galactoside alpha-2,3-Sialyltransferase
Glycoconj J. 2008 Jan;25(1):59-68
17914671
J Biol Chem. 1993 Jul 5;268(19):13971-7
8314763
Exp Cell Res. 2008 Oct 1;314(16):2941-50
18703050
Cancer Res. 2005 Jun 1;65(11):4645-52
15930282
BMC Cancer. 2009 Oct 07;9:357
19811634
Rev Fr Transfus Immunohematol. 1987 Dec;30(5):699-708
3330858
Cancer Lett. 1998 Nov 27;133(2):151-60
10072164
Gynecol Oncol. 2003 Jun;89(3):395-401
12798701
Oncol Rep. 2002 Nov-Dec;9(6):1251-5
12375029
Cancer Sci. 2007 Jul;98(7):1000-5
17459061
Int J Biochem Cell Biol. 2010 Jan;42(1):80-9
19781661
Methods Mol Biol. 2000;132:365-86
10547847
Curr Med Chem. 2007;14(4):377-86
17305540
Eur J Biochem. 2003 Mar;270(5):950-61
12603328
Glycoconj J. 1997 Aug;14(5):577-84
9298690
Cancer Res. 1999 Mar 15;59(6):1356-61
10096570
Glycobiology. 1998 Jun;8(6):605-13
9592127
Glycobiology. 2005 Aug;15(8):805-17
15843597
J Biol Chem. 1992 Oct 15;267(29):21011-9
1400416
Biochim Biophys Acta. 2006 Apr;1760(4):685-92
16439063
Int J Biol Markers. 2003 Apr-Jun;18(2):116-22
12841680
Expert Opin Ther Targets. 2007 Nov;11(11):1473-91
18028011
J Immunol. 2002 Jul 15;169(2):983-92
12097405
Semin Liver Dis. 1993 Feb;13(1):60-71
8446909
Int J Pancreatol. 1992 Apr;11(2):125-35
1376758
J Biol Chem. 1982 Nov 25;257(22):13845-53
7142180
J Biol Chem. 1994 Jan 14;269(2):1394-401
8288606
Br J Cancer. 2001 Jun 1;84(11):1556-63
11384108
J Cell Mol Med. 2010 Jan;14(1-2):165-74
19627399
Gut. 2000 Mar;46(3):359-66
10673297
Hepatology. 2003 Mar;37(3):674-85
12601365
Pancreas. 1991 Jul;6(4):448-58
1678888
EMBO J. 1999 Mar 15;18(6):1516-25
10075923
Cancer Res. 2001 Sep 15;61(18):6822-9
11559557
Arch Biochem Biophys. 2004 Jun 15;426(2):122-31
15158662
Cancer Res. 2000 Mar 1;60(5):1449-56
10728712
J Surg Oncol. 1998 Feb;67(2):77-84
9486777
Int J Cancer. 1997 May 16;71(4):556-64
9178808
Oncology. 2003;65(2):139-45
12931020
Br J Cancer. 1999 Jun;80(8):1169-74
10376968
Cancer Sci. 2004 May;95(5):377-84
15132763
Science. 2003 Dec 5;302(5651):1704-9
14657486
Eur J Cancer. 1997 May;33(6):931-41
9291818
Cancer Res. 1994 May 15;54(10):2667-72
8168095
J Ovarian Res. 2008 Oct 01;1(1):3
19014651
J Cancer Res Clin Oncol. 2002 Nov;128(11):617-20
12458342
Biochimie. 2001 Aug;83(8):727-37
11530204
Biochemistry. 2005 Nov 29;44(47):15619-35
16300412
Anticancer Res. 1997 Jan-Feb;17(1A):293-9
9066667
Biochem Biophys Res Commun. 1996 Nov 12;228(2):324-7
8920913
J Biol Chem. 2002 Nov 29;277(48):45719-28
12235148
Mol Cell Biochem. 2009 Nov;331(1-2):81-8
19415457
Hepatology. 2005 Mar;41(3):451-9
15723297
Nature. 2007 Apr 26;446(7139):1023-9
17460663
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13789-94
12370411
Mol Cell Biochem. 2003 Dec;254(1-2):193-202
14674698
Jpn J Clin Oncol. 1997 Jun;27(3):135-9
9255266
Gastroenterology. 1998 Mar;114(3):462-70
9496936
Nature. 2009 Jun 18;459(7249):1005-9
19421193
Cancer Res. 1986 Mar;46(3):1553-61
3510728
Pathol Res Pract. 2000;196(4):259-63
10782470
Biochem Biophys Res Commun. 1993 Jul 15;194(1):375-82
8333853
Gynecol Oncol. 2005 Feb;96(2):415-22
15661230
Biochem Biophys Res Commun. 1999 Mar 24;256(3):631-6
10080950
Eur J Biochem. 2001 Jun;268(12):3501-12
11422380
Cancer Res. 1988 Jan 15;48(2):475-82
3335015
J Cancer Res Clin Oncol. 2002 Apr;128(4):189-96
11935309
Oncology. 2005;69(5):436-44
16319516
Glycoconj J. 2005 Mar;22(3):135-44
16133834
Gastroenterology. 1996 May;110(5):1354-67
8613039
Eur J Biochem. 1996 Dec 15;242(3):674-81
9022696
Int J Cancer. 1996 Aug 22;69(4):290-4
8797870
Shi Yan Sheng Wu Xue Bao. 2002 Dec;35(4):271-7
15346983
Glycoconj J. 2001 Nov-Dec;18(11-12):841-50
12820717
Cancer Res. 1998 Sep 15;58(18):4066-70
9751611
Gynecol Oncol. 2002 Jul;86(1):45-52
12079299
Hepatobiliary Pancreat Dis Int. 2004 May;3(2):292-5
15138129
Dis Colon Rectum. 1997 Apr;40(4):420-31
9106690